RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/30326995/ below:

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Review

. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Affiliations

¹ National Centre for Immunisation Research and Surveillance, Westmead, Australia.
² VCS Population Health, VCS Foundation, East Melbourne, Australia.
³ School of Population and Global Health, University of Melbourne, Parkville, Australia.
⁴ Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
⁵ The Kirby Institute, University of New South Wales, Sydney, Australia.
⁶ Sydney Sexual Health Centre, Sydney Hospital, Sydney, Australia.
⁷ Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, North Adelaide, Australia.
⁸ Robinson Research Institute and Adelaide Medical School, University of Adelaide, North Adelaide, Australia.

PMID: 30326995
PMCID: PMC6194907
DOI: 10.2807/1560-7917.ES.2018.23.41.1700737

Item in Clipboard

Review

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Cyra Patel et al. Euro Surveill. 2018 Oct.

. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. Affiliations

¹ National Centre for Immunisation Research and Surveillance, Westmead, Australia.
² VCS Population Health, VCS Foundation, East Melbourne, Australia.
³ School of Population and Global Health, University of Melbourne, Parkville, Australia.
⁴ Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
⁵ The Kirby Institute, University of New South Wales, Sydney, Australia.
⁶ Sydney Sexual Health Centre, Sydney Hospital, Sydney, Australia.
⁷ Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, North Adelaide, Australia.
⁸ Robinson Research Institute and Adelaide Medical School, University of Adelaide, North Adelaide, Australia.

PMID: 30326995
PMCID: PMC6194907
DOI: 10.2807/1560-7917.ES.2018.23.41.1700737

Item in Clipboard

Abstract

Background: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide.

Aim: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine.

Methods: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden.

Results: Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible women have been observed. Reductions in genital warts incidence and HPV prevalence among heterosexual men of similar age were observed before introduction of the male vaccination programme, indicating a substantial herd effect. 9vHPV vaccine is expected to prevent up to 90% of cervical and 96% of anal cancers. Of an estimated 1,544 HPV-associated cancers in 2012, 1,242 would have been preventable by the 4vHPV vaccine and an additional 187 anogenital cancers by the 9vHPV vaccine.

Conclusions: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.

Keywords: HPV; epidemiology; human papillomavirus; immunisations; vaccine-preventable diseases; vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared. Helen Marshall, Julia Brotherton, Basil Donovan and Kristine Macartney are members of the Australian Technical Advisory Group on Immunisation’s (ATAGI’s) HPV Working Party (November 2014 to February 2018). This manuscript reflects the views of the authors only, and does not necessarily represent the views of ATAGI. Julia Brotherton and Basil Donovan have received funding for HPV-related research from manufacturers of HPV vaccines (Seqirus (JB and BD) and MSD (JB)) and the Australian Department of Health (BD). Helen Marshall’s institution receives funding for vaccine trials sponsored by GlaxoSmithKline and Seqirus. No specific funding was provided for this review, and none of the co-authors receive any personal financial benefits from industry sponsors.

Figures
Figure

Trends in high-grade cervical abnormalities in…

Figure

Trends in high-grade cervical abnormalities in women by age group before and after commencement…

Figure

Trends in high-grade cervical abnormalities in women by age group before and after commencement of the female HPV vaccination programme, Australia, 2004–2014